Results 21 to 30 of about 3,523 (219)

Functional and structural insights into HCMV terminase accessory proteins pUL77 and pUL93 [PDF]

Journal of Virology
Human cytomegalovirus (HCMV) is a significant cause of morbidity and mortality in immunocompromised and congenitally infected patients. Current antiviral therapies, primarily targeting the viral DNA polymerase, are limited by toxicity and resistance ...
C. Gourin, F. Di Meo, C. Delmon, S. Alain, S. Hantz   +4 more
doaj   +2 more sources

Cytomegalovirus IL-10 in Plasma as a Marker of Active Infection in Allogeneic Hematopoietic Transplant Recipients: An Exploratory Study. [PDF]

J Med Virol
ABSTRACT We investigated whether plasma cytomegalovirus (CMV) IL‐10 (cmvIL‐10) levels could serve as a biomarker of active CMV replication in allogeneic hematopoietic transplant recipients (allo‐HCT) in the presence or absence of letermovir (LMV) prophylaxis. A total of 189 leftover plasma samples that tested positive for CMV DNA (Alinity m CMV assay),
Sánchez-Simarro Á, Albert E, Giménez E, Colomer E, Pérez A, Piñana JL, Solano C, Navarro D.   +7 more
europepmc   +2 more sources

Real-World Evaluation of Letermovir Use in Kidney Transplant Recipients: Drug Interactions, Safety, and Impact on Renal Function [PDF]

Transplant International
Ilies Benotmane, Ilies Benotmane, Betoul Schvartz, Cyril Garrouste, Florence Runyo, Charlotte Boud’hors, Charlotte Boud’hors, Gauthier Flahaut, Clément Danthu, Dominique Bertrand, Sophie Caillard, Sophie Caillard   +11 more
doaj   +2 more sources

Real-World Use of Letermovir and Maribavir for CMV Prophylaxis and Treatment in Solid Organ Transplant Recipients: Clinical Outcomes and Resistance Patterns From a Dual-Center Cohort. [PDF]

Pharmacotherapy
ABSTRACT Background Cytomegalovirus (CMV) is a major opportunistic infection in solid organ transplant (SOT) recipients. Although valganciclovir is first‐line for CMV treatment, its use may be limited by resistance and myelotoxicity. Letermovir (LET) and maribavir (MBV) are increasingly used as alternative therapies, though real‐world outcomes remain ...
Xu MT, Wright A, Mah A, Matic N, Lowe C, Hong C, Belga S, Tsai WP.   +7 more
europepmc   +2 more sources

Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study

Viruses, 2023
The prevention and management of cytomegalovirus (CMV) reactivation is important to improve the outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) recipients.
Dukhee Nho, Raeseok Lee, Sung-Yeon Cho, Dong-Gun Lee, Eun-Jin Kim, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Yoo-Jin Kim, Seok Lee, Hee-Je Kim   +10 more
doaj   +1 more source

Letermovir

Drugs of the Future, 2013
null Verghese, P.S., null Schleiss, M.R.
openaire   +3 more sources

Developing a mechanistic understanding of the nonlinear pharmacokinetics of letermovir and prospective drug interaction with everolimus using physiological‐based pharmacokinetic modeling

Clinical and Translational Science, 2023
Letermovir is approved for use in cytomegalovirus‐seropositive hematopoietic stem cell transplant recipients and is investigated in other transplant settings.
Karsten Menzel, Yuhsin Kuo, Dapeng Chen, Georgy Hartmann, Ying‐Hong Wang, Carolyn R. Cho, Jacqueline B. McCrea, Kazuhiko Asari   +7 more
doaj   +1 more source

Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study

Vaccines, 2021
Background: Real-life data on the administration of letermovir as cytomegalovirus (CMV) primary prophylaxis after allogeneic hematopoietic cell transplantation (HCT) remain limited. Methods: We conducted a retrospective single-center matched cohort study,
Léna Royston, Eva Royston, Stavroula Masouridi-Levrat, Nathalie Vernaz, Yves Chalandon, Christian Van Delden, Dionysios Neofytos   +6 more
doaj   +1 more source

New Insights Into Factors Shaping CMV-Specific T-Cell Polyfunctionality After Hematopoietic Cell Transplantation. [PDF]

Am J Hematol
ABSTRACT Polyfunctional cytomegalovirus (CMV)‐specific T cells are critical for antiviral immunity in allogeneic hematopoietic cell transplantation (HCT) recipients. However, gaps remain in managing refractory CMV and optimizing virus‐specific cellular therapy (VST).
Sadowska-Klasa A, Lim FY, Xie H, Zamora D, Stevens-Ayers T, Leisenring WM, Edmison BC, De Rosa SC, Mielcarek M, Boeckh M.   +9 more
europepmc   +2 more sources

Drug interactions of tacrolimus with letermovir and azole antifungals following hematopoietic stem cell transplantation: A retrospective observational analysis

Pharmacology Research & Perspectives, 2023
Tacrolimus interacts with letermovir and azole antifungals, whereas letermovir has nonuniform effects on the pharmacokinetics of azole antifungals.
Yuri Shinogi, Toshinori Hirai, Miki Ishibashi, Kazuko Ino, Isao Tawara, Takuya Iwamoto   +5 more
doaj   +1 more source